Hereditary Disease Foundation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hereditary Disease Foundation
Over the course of two decades, three leading cancer investigators from Memorial Sloan-Kettering Cancer Center (MSKCC), Paul Marks, MD, Richard Rifkind, MD, and Victoria Richon, PhD, along with Ronald Breslow, PhD of Columbia University, have performed research with the objective to develop safer, more effective cancer treatments. Their pioneering work focused on an emerging class of anti-tumor agents-histone deacetylase (HDAC) inhibitors. Now the team of four hopes to translate lab research to drug development in Aton Pharma Inc.
- Academic and Research Institutions